Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells

Kiyoyuki Ogata, Kazuma Sei, Leonie Saft, Naoya Kawahara, Matteo G.Della Porta, Nicolas Chapuis, Yumi Yamamoto

Research output: Contribution to journalArticle

Abstract

Diagnosis of myelodysplastic syndromes (MDS) is not straightforward when objective data, such as blast excess and abnormal cytogenetics, are lacking. Expert laboratories use flow cytometry (FCM) to help diagnose MDS. However, most of FCM protocols for MDS are complex, requiring a high level of expertise and high cost. We have reported a FCM mini-panel consisting of four FCM parameters (so-called Ogata score), which is simple to conduct and inexpensive. In this paper, to refine this mini-panel, we have introduced a new FCM parameter, which quantifies CD33 expression on CD34+ cells (called Granulocyte/CD34 cell CD33 ratio). Bone marrow cells from MDS without blast excess (low-grade MDS) and controls were stained with CD34, CD45, and CD33 and analyzed for five parameters (“Granulocyte/CD34 cell CD33 ratio” plus four parameters in the Ogata score). By a multivariate logistic regression model, only three parameters, including “Granulocyte/CD34 cell CD33 ratio” had statistically significant power for diagnosing low-grade MDS. Based on the results, we constructed a new scoring system, which showed approximately 50% sensitivity and more than 95% specificity in diagnosing low-grade MDS. Our revised mini-panel is suitable for screening samples suspected for MDS and provides a basis for further improvement in diagnostic FCM protocols for MDS.

Original languageEnglish
Pages (from-to)75-81
Number of pages7
JournalLeukemia Research
Volume71
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Myelodysplastic Syndromes
Flow Cytometry
Granulocytes
Logistic Models
Cytogenetics
Bone Marrow Cells
Costs and Cost Analysis

Keywords

  • CD33
  • CD34
  • Flow cytometry
  • Myelodysplastic syndromes
  • Ogata score
  • Side scatter

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes : Introducing a parameter quantifying CD33 expression on CD34+ cells. / Ogata, Kiyoyuki; Sei, Kazuma; Saft, Leonie; Kawahara, Naoya; Porta, Matteo G.Della; Chapuis, Nicolas; Yamamoto, Yumi.

In: Leukemia Research, Vol. 71, 01.08.2018, p. 75-81.

Research output: Contribution to journalArticle

Ogata, Kiyoyuki ; Sei, Kazuma ; Saft, Leonie ; Kawahara, Naoya ; Porta, Matteo G.Della ; Chapuis, Nicolas ; Yamamoto, Yumi. / Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes : Introducing a parameter quantifying CD33 expression on CD34+ cells. In: Leukemia Research. 2018 ; Vol. 71. pp. 75-81.
@article{d8965dbf093246708cb7086fcae69b08,
title = "Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells",
abstract = "Diagnosis of myelodysplastic syndromes (MDS) is not straightforward when objective data, such as blast excess and abnormal cytogenetics, are lacking. Expert laboratories use flow cytometry (FCM) to help diagnose MDS. However, most of FCM protocols for MDS are complex, requiring a high level of expertise and high cost. We have reported a FCM mini-panel consisting of four FCM parameters (so-called Ogata score), which is simple to conduct and inexpensive. In this paper, to refine this mini-panel, we have introduced a new FCM parameter, which quantifies CD33 expression on CD34+ cells (called Granulocyte/CD34 cell CD33 ratio). Bone marrow cells from MDS without blast excess (low-grade MDS) and controls were stained with CD34, CD45, and CD33 and analyzed for five parameters (“Granulocyte/CD34 cell CD33 ratio” plus four parameters in the Ogata score). By a multivariate logistic regression model, only three parameters, including “Granulocyte/CD34 cell CD33 ratio” had statistically significant power for diagnosing low-grade MDS. Based on the results, we constructed a new scoring system, which showed approximately 50{\%} sensitivity and more than 95{\%} specificity in diagnosing low-grade MDS. Our revised mini-panel is suitable for screening samples suspected for MDS and provides a basis for further improvement in diagnostic FCM protocols for MDS.",
keywords = "CD33, CD34, Flow cytometry, Myelodysplastic syndromes, Ogata score, Side scatter",
author = "Kiyoyuki Ogata and Kazuma Sei and Leonie Saft and Naoya Kawahara and Porta, {Matteo G.Della} and Nicolas Chapuis and Yumi Yamamoto",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.leukres.2018.07.009",
language = "English",
volume = "71",
pages = "75--81",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes

T2 - Introducing a parameter quantifying CD33 expression on CD34+ cells

AU - Ogata, Kiyoyuki

AU - Sei, Kazuma

AU - Saft, Leonie

AU - Kawahara, Naoya

AU - Porta, Matteo G.Della

AU - Chapuis, Nicolas

AU - Yamamoto, Yumi

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Diagnosis of myelodysplastic syndromes (MDS) is not straightforward when objective data, such as blast excess and abnormal cytogenetics, are lacking. Expert laboratories use flow cytometry (FCM) to help diagnose MDS. However, most of FCM protocols for MDS are complex, requiring a high level of expertise and high cost. We have reported a FCM mini-panel consisting of four FCM parameters (so-called Ogata score), which is simple to conduct and inexpensive. In this paper, to refine this mini-panel, we have introduced a new FCM parameter, which quantifies CD33 expression on CD34+ cells (called Granulocyte/CD34 cell CD33 ratio). Bone marrow cells from MDS without blast excess (low-grade MDS) and controls were stained with CD34, CD45, and CD33 and analyzed for five parameters (“Granulocyte/CD34 cell CD33 ratio” plus four parameters in the Ogata score). By a multivariate logistic regression model, only three parameters, including “Granulocyte/CD34 cell CD33 ratio” had statistically significant power for diagnosing low-grade MDS. Based on the results, we constructed a new scoring system, which showed approximately 50% sensitivity and more than 95% specificity in diagnosing low-grade MDS. Our revised mini-panel is suitable for screening samples suspected for MDS and provides a basis for further improvement in diagnostic FCM protocols for MDS.

AB - Diagnosis of myelodysplastic syndromes (MDS) is not straightforward when objective data, such as blast excess and abnormal cytogenetics, are lacking. Expert laboratories use flow cytometry (FCM) to help diagnose MDS. However, most of FCM protocols for MDS are complex, requiring a high level of expertise and high cost. We have reported a FCM mini-panel consisting of four FCM parameters (so-called Ogata score), which is simple to conduct and inexpensive. In this paper, to refine this mini-panel, we have introduced a new FCM parameter, which quantifies CD33 expression on CD34+ cells (called Granulocyte/CD34 cell CD33 ratio). Bone marrow cells from MDS without blast excess (low-grade MDS) and controls were stained with CD34, CD45, and CD33 and analyzed for five parameters (“Granulocyte/CD34 cell CD33 ratio” plus four parameters in the Ogata score). By a multivariate logistic regression model, only three parameters, including “Granulocyte/CD34 cell CD33 ratio” had statistically significant power for diagnosing low-grade MDS. Based on the results, we constructed a new scoring system, which showed approximately 50% sensitivity and more than 95% specificity in diagnosing low-grade MDS. Our revised mini-panel is suitable for screening samples suspected for MDS and provides a basis for further improvement in diagnostic FCM protocols for MDS.

KW - CD33

KW - CD34

KW - Flow cytometry

KW - Myelodysplastic syndromes

KW - Ogata score

KW - Side scatter

UR - http://www.scopus.com/inward/record.url?scp=85049851552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049851552&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2018.07.009

DO - 10.1016/j.leukres.2018.07.009

M3 - Article

AN - SCOPUS:85049851552

VL - 71

SP - 75

EP - 81

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -